Could the next generation of type 1 diabetes treatments come from better timing, better combinations, or better cells? Across the UK, researchers are working together in the #Type1DiabetesGrandChallenge to find answers. They're asking: - Could the time of day an immunotherapy is given make it more effective at slowing the immune attack? - Could combining immunotherapies, to target different parts of the immune system, provide better protection for insulin-producing cells? - How can we strengthen insulin-producing cells before transplantation so they're more likely to survive in the body? Mollie Hillis travelled from Birmingham to Edinburgh to meet the teams behind this research and discover how collaboration is accelerating progress towards new treatments. Because answering big questions takes big ideas - and, importantly, people working together. Read more: bit.ly/4yeq7qN #T1D #GBDoc #Research @DiabetesUK

Does your family plan on joining us at our Discovery Day in London next Saturday? We'd love to hear from you! 👂 We're looking for families to join us for a quick and informal session, to help us understand the information and support that were most useful to you since diagnosis. Your opinion will help us shape and improve the support we give to newly diagnosed families. 💙 We're incredibly thankful to The Bukhman Foundation for supporting our Community Engagement work! Tap the link and sign up today: bit.ly/3UUYNiB 🔗 #DiscoveryDay #GBDoc #BreakthroughT1D

We are recruiting three volunteers for the Scientific Advisory Council (SAC)🚨 The purpose of the SAC is to provide insightful, independent advice and critical opinions to Breakthrough T1D by guiding our research decisions, policies and position statements.   We are looking for: - One expert by experience (18-22 y/o) - One healthcare professional (dietitian)  - One clinical researcher Find out more about these roles: bit.ly/4cB3xQk 🔗

Could the time an immunotherapy treatment is given make it more effective for people with type 1 diabetes? That's the question Dr James Pearson and his team are exploring. Their research is investigating whether delivering treatment when protective immune cells (Tregs) are most 'awake' could improve its ability to slow or prevent the immune system from attacking insulin-producing cells. It's an innovative approach that could help unlock more effective immunotherapies for type 1 diabetes. Read more about the project here: bit.ly/49w2flG @DiabetesUK #Type1Diabetes #GBDoc #Type1DiabetesGrandChallenge

Today, history has been made: NICE has approved teplizumab for use on the NHS in England and Wales. Teplizumab is the first ever immunotherapy that can delay the onset of type 1 diabetes symptoms for people in the early stages of the condition. For the first time, we’re not just managing type 1 - we’re changing its course. This milestone means many things. But above all, it means time. More time to simply be a child. A reduction in emergency diagnoses and serious complications like diabetic ketoacidosis. A softer landing for individuals and families suddenly facing management of a life-long condition, and with it, renewed hope for the future. And this achievement belongs to you, our community. Breakthrough T1D funded early-stage research and the clinical trials that made teplizumab a reality. This breakthrough was made possible by your belief and support. Together, we are changing what’s possible. 💙 Read the full story here: bit.ly/4oJQzoo #GBDoc #Type1Diabetes #Teplizumab